Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05024552
Title Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
Recruitment Suspended
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

acute myeloid leukemia

Therapies

CPX-351 + Gilteritinib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST